Results 11 to 20 of about 45,933 (222)
Safety and Efficacy of Everolimus in Adult Patients with Neuroendocrine Tumors
Clinical Medicine Insights: Oncology, 2012 Neuroendocrine tumors (NETs) consist of a diverse family of tumors which are derived from the neuroendocrine system. Most NETs are well or moderately differentiated tumors with a relatively indolent growth pattern.
Paul E. Oberstein, M. Wasif Saif
doaj +2 more sources
The use of everolimus in renal-transplant patients
International Journal of Nephrology and Renovascular Disease, 2009 Julio PascualServicio de Nefrología, Hospital Ramón y Cajal, 28034 Madrid, SpainAbstract: Despite advances in immunosuppressive therapy, long-term renal-transplantation outcomes have not significantly improved over the last decade ...
Julio Pascual
doaj +1 more source
Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma [PDF]
, 2013 This study aimed at determining the recommended dose of the mammalian target of rapamycin inhibitor everolimus in combination with mitomycin C (MMC) in patients with previously treated metastatic esophagogastric cancer.
Werner, Dominique +5 more
core +1 more source
Anti-Tumor Effect of the Mammalian Target of Rapamycin Inhibitor Everolimus in Oral Squamous Cell Carcinoma [PDF]
, 2015 The mammalian target of rapamycin (mTOR) has recently emerged as a promising target for therapeutic anti-cancer interventions in several human tumors. In present study, we investigated the expression of mTOR, and subsequently examined its relationship ...
Kawakita, Akiko +6 more
core +1 more source
EJNMMI Research, 2020 Purpose Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA0,TYR3-octreotate ([177Lu]Lu-DOTA-TATE) and the mechanistic target of rapamycin (mTOR) inhibitor everolimus are both approved for the treatment of neuroendocrine tumours (NET ...
Johannes Zellmer +11 more
doaj +1 more source
Frontiers in Endocrinology, 2022 The mammalian target of rapamycin (mTOR) inhibitor everolimus has been shown to display antiproliferative effects on a wide spectrum of tumors. In vitro studies demonstrated that everolimus inhibited pituitary neuroendocrine tumor (PitNET) cell growth in
Federica Mangili +18 more
doaj +1 more source
Cerrahpaşa Medical Journal, 2019 Pneumonitis is a reported side effect of treatment with mammalian target of rapamycin inhibitors. In this report, we present a case of everolimus-related pneumonitis that occurred after treatment switching from sirolimus to everolimus.
Eda Kaya +5 more
doaj +1 more source
The novel mTOR inhibitor RAD001 (Everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells [PDF]
, 2007 Background/Aim: Tumors exhibiting constitutively activated PI(3) K/Akt/mTOR signaling are hypersensitive to mTOR inhibitors such as RAD001 (everolimus) which is presently being investigated in clinical phase II trials in various tumor entities, including
Brand, Stephan +8 more
core +1 more source
Thoracic Cancer, 2023 Background Triple‐positive breast cancer (TPBC) is highly invasive and lacks well‐established treatment strategies, especially in patients with advanced stage disease.
Yujing Tan +9 more
doaj +1 more source
Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer
Breast Cancer Research, 2017 Background The mammalian target of rapamycin inhibitor everolimus is approved as an antitumor agent in advanced estrogen receptor-positive breast cancer.
Andrew J. Browne +8 more
doaj +1 more source